Efficacy and safety of azvudine in symptomatic adult COVID-19 participants who are at increased risk of progressing to critical illness: a study protocol for a multicentre randomized double-blind placebo-controlled phase III trial

Table 2 Arms and interventions

Arm	No. of participants	Interventions
Placebo group	548	Azvudine po. 5 mg once daily for 7 days + COVID-19 treatment regimens other than antiviral medications^a
Treatment group	548	Placebo po. five tablets once daily for 7 days + COVID-19 treatment regimens other than antiviral medications^a

^aCOVID-19 treatment regimens other than antiviral medications, including but not limited to oxygen therapy, respiratory support, symptomatic medications, glucocorticosteroids, and biologic agents such as interleukin-6 receptor inhibitors and tyrosine kinase inhibitors. Among other things, the programme does not restrict the use of nonsteroidal anti-inflammatory drugs to avoid adding additional discomfort to the subjects

ISSN: 1745-6215